| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Previous Article | Next Article ![]()
The University of Texas Southwestern Medical Center, Dallas, TX
* To whom correspondence should be addressed. Email:
robert.hardy{at}utsouthwestern.edu.
To evaluate empiric therapy with trimethoprim-sulfamethoxazole or doxycycline for outpatient SSTI in an area of high MRSA prevalence a randomized, prospective, open-label investigation was performed. The overall clinical failure rate was 9% with all failures occurring in the trimethoprim-sulfamethoxazole group. However, there was no significant difference in the clinical failure rate of empiric trimethoprim-sulfamethoxazole compared with doxycycline therapy.
Copyright (c) 2007, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights Reserved.
Empiric Therapy with Trimethoprim-Sulfamethoxazole or Doxycycline for Outpatient Skin and Soft Tissue Infections in an Area of High MRSA Prevalence: A Prospective Randomized Trial
![]()
Abstract
This article has been cited by other articles:
| Clin. Vaccine Immunol. | Clin. Microbiol. Rev. |
|---|---|
| J. Clin. Microbiol. | ALL ASM JOURNALS |